joining and all Jeremy, thanks webcast Thank you, today. the of us you to call for on the and
commenting financial revenue and in While Craig minutes, reported by detail revenue. to review will on begin I results specifically our in a want few year-to-date the
million, of the first of the in the of in compared to the period decrease million. comparable months the as was year months compared the was decline first $XXX,XXX six CGuard represents through as XX% of three for XXXX. Total XXXX. to XX% revenue a year a period This or $X.X $X.X comparable
of you inability in As equipment of during that sterilize issues the partner resulted experienced the to product our quarter. quarter most this year, for sterilization first our recall,
first three shortage to customers year. the months ship the had our of was of that we for such, majority distributors and a this of As product available to
immediately comprehensive engaged in other thus the provider issue. in resolving our Body conducted submitted testing early sterilization to a all European package approved we Notified the required, supplier completely subsequently However, our new April, and validation which
from The the XXXX. bill in. maintained product us basis and inventory to year-end was come is This on mostly that was to we from react that an first they inventory quarter orders in ongoing shipped allow as quickly
CGuard consequences supply of had lack CGuard the the However, our impact to had period CGuard inability major Examples QX. had during the centers reluctance markets been and to unintended were not open new second but where their in these in the lost in procedures revenue, and backlog were due to of of this unintended customers place consequences the during consequences ongoing market some cleared. our a as of to QX key orders orders quarter sales of only the time on additional typical
available second these is on the and has for distribution I that is issues remedying them and talking back with been a restoring was confidence. been of news many procedures. of onetime carotid this partners result and have the a spent now supplier QX and have reassuring that We quarter of shelves distribution track issue our partners personally issues with and meeting resolved. sterilization to our that as been our good CGuard on their back The and hospitals getting
discussions orders. the challenging, placing are our the partners appropriately While were
first of down compared year XX% our have to nearly almost three to versus XXXX. the half due anticipated months out be the of could market XXXX of us for to being One last
time revenue in However, we XXXX. period versus the catch XX% managed a decrease just CGuard to with completely up same almost in
States. United the to turning Now,
allow us as our we midyear. occurred This planned, to application studies at application approved, clinical Exemption questions commence U.S. the the conditional the the our IDE disapproval days XX an United know, application, approval, on or on submission or to IDE CGuard on approval, would Typically you Device FDA responses has As atypical. within planned in with additional FDA which submitting an States. and Investigational not is if
the body to significant our be optimistic significant in profile of would the this the If important that of novel development safety it Given evidence most CGuard, remain clinical of would as be our world’s market. device confirming of approved. will allow we a point inflection this so, IDE us Company begin
warranted. as will provide We further updates
United of requirements, introduce higher into have territories, Japan. regulatory CGuard China States, of Outside and to which meaningful Korea, notably Taiwan, many working we most are South
the year. This that the devices. continue approve Brazil disease end artery addition, will is attractive as carotid treats significant CGuard In ANVISA, has carotid in anticipate fifth the by and we market world pricing the largest is regulatory Brazil in body that this for to of currently
vascular that experience of word major Centers last using is late the surgeons device. our physicians and training which began seeks A hospitals This target distribution wish year provide component Excellence our initiative growth in including to partners convert of multifaceted to physicians allows interested in strategy real long-term, with our of to key our using CGuard and to product.
with have the majority perform the device. surgeons pointed vascular in of out surgical an which alternative carotid treating the procedures vast to As past, invasive the are disease endarterectomy we
CGuard its and surgical patients to us, undergo and have numbers would an profile. educating and efficacy endarterectomy growth an So, such safety who associated for procedures of is longer risk important no them as countless would the such benefit on driver of invasive
an stents next are visiting in we CGuard use data of Excellence first specialties. well on CGuard opinion endarterectomy. to respected KOL the live stents, -- generation hands These their and of basis efficacy investigate partners allowing The to them own in fostered carotid a generating who their clinical clinicians in leaders ongoing the specific are to Centers compared of the sessions, well Excellence in on In the clinic, clinical generation our key number Centers and carotid important then clinics. or double KOLs on carotid compelling safety cases, ready CGuard return data. or train conventional of and of educate also by patient are clinical We other layer
and Excellence Centers Germany, Italy, results in of positive. opened been To-date, extremely Slovenia, have Spain, Poland we’ve and
this allow as Excellence Looking ahead, the such we and At vascular to Centers about of in us Netherlands typically per Belgium. half activities further expand to open UK, the to new important program our to quarter, of new intend them surgery. present, centers territories XX XX
broadest increase. a our and As our these will population the CGuard long uptake. will to driving goal and is program numbers the Centers patient awareness to of available go expanse, Excellence towards make way possible It
minimal surgery. story. you patient carotid has carotid be device CGuard of than outcomes invasive the a carotid concern artery best-in-class a for deliver MicroNet which stroke artery that far treatment highly superior major designed back reduce step our may of disease procedures, It both proprietary a incidence who around to can technology conventional to and treating stents a differentiated open following is carotid historically for Taking those even relative eliminate or of platform is to dramatically been invasively physician. and new the patients less endarterectomy strut
the vessels believe embolization treatment an external wall carotid is CGuard the This by is designed carotid a blood of high maintaining stenosis. we prevent that and to behind of while to other in artery MicroNet, the trapping the arterial branch potential important breakthrough emboli and grade the flow represents profusion feed new late brain. against paradigm
are address just can approximately but on either stents market CGuard untreated. could diagnosed that estimate currently treated who patients grow based who or endarterectomy. $X are conventional a billion million can This people opportunity, exponentially if X.X the near-term carotid we with opportunity We convert
recognize from As and assess awareness of grow, proactive allow additional a CGuard the We queries partners always a business the inbound to coming collaborators. this development on more effectively been implement focused we to Business key inquiries business to and resources weeks a to have strategy. of seen inquiries has strategy continues our plan need more to potential in place recent increase pillar. with in add long-term development these focus us the pillar growth development and we notable
turn the over With call for of review to that, Craig the I’ll financials. a
